Transforming Growth Factor-β-Activated Kinase 1 Is Required for Human FcγRIIIb-Induced Neutrophil Extracellular Trap Formation

Omar Rafael Alemán1, Nancy Mora1, Ricarda Cortes-Vieyra1, Eileen Uribe-Querol2 and Carlos Rosales1*

1 Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 2 División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Ciudad de México, Mexico

Neutrophils (PMNs) are the most abundant leukocytes in the blood. PMN migrates from the circulation to sites of infection where they are responsible for antimicrobial functions. PMN uses phagocytosis, degranulation, and formation of neutrophil extracellular traps (NETs) to kill microbes. Several stimuli, including bacteria, fungi, and parasites, and some pharmacological compounds, such as Phorbol 12-myristate 13-acetate (PMA), are efficient inducers of NETs. Antigen–antibody complexes are also capable of inducing NET formation. Recently, it was reported that FcγRIIIb cross-linking induced NET formation similarly to PMA stimulation. Direct cross-linking of FcγRIIA or integrins did not promote NET formation. FcγRIIIb-induced NET formation presented different kinetics from PMA-induced NET formation, suggesting differences in signaling. Because FcγRIIIb also induces a strong activation of extracellular signal-regulated kinase (ERK) and nuclear factor Elk-1, and the transforming growth factor-β-activated kinase 1 (TAK1) has recently been implicated in ERK signaling, in the present report, we explored the role of TAK1 in the signaling pathway activated by FcγRIIIb leading to NET formation. FcγRIIIb was stimulated by specific monoclonal antibodies, and NET formation was evaluated in the presence or absence of pharmacological inhibitors. The antibiotic LL Z1640-2, a selective inhibitor of TAK1 prevented FcγRIIIb-induced, but not PMA-induced NET formation. Both PMA and FcγRIIIb cross-linking induced phosphorylation of ERK. A MEK (ERK kinase)-specific inhibitor was able to prevent ERK phosphorylation induced by both PMA and FcγRIIIb. These data show for the first time that FcγRIIIb cross-linking activates TAK1, and that this kinase is required for triggering the MEK/ERK signaling pathway to NETosis.

Keywords: immunoglobulin, immunoreceptor, inflammation, neutrophil, DNA, TAK1, ERK
INTRODUCTION

Neutrophils are innate immune cells that migrate from the circulation to sites of inflammation or infection. Classically, neutrophils are considered the first line of defense since they are the first cells to appear at the affected site, and they display important antimicrobial functions (1). Neutrophils use phagocytosis, degranulation, and formation of neutrophil extracellular traps (NETs) to kill microbes (2, 3). NETs are formed through a unique cell death program named “NETosis” that involves first degradation of the nuclear membrane and chromatin expansion into the cytosol, while the cell membrane remains intact. Later, 3 or 4 h after stimulation, the cell membrane breaks, and the chromatin fibers get expelled outside the cell, creating a net-like structure. NET fibers are composed of chromatin covered with histones (4) and antimicrobial proteins derived from the neutrophil granules, such as the bactericidal/permeability-increasing protein (BPI), elastase, myeloperoxidase, lactoferrin, and metalloprotease 9 (2, 5). NETs prevent further spread of pathogens because they function as a physical barrier where microorganisms get trapped and because they bring antimicrobial proteins in close proximity of pathogens. Thus, NETs can kill microorganisms extracellularly and independently of phagocytosis (6).

Human neutrophils express constitutively two IgG antibody receptors: FcγRIa (CD32a) and FcγRIIb (CD16b) (7). FcγRIa consists of a single polypeptide chain bearing an ITAM on its cytoplasmic domain (8). This ITAM confers on FcγRIa the ability to initiate signaling events that regulate cell responses, including phagocytosis, cytokine production, and antibody-dependent cell-mediated cytotoxicity (9). FcγRIIib is present exclusively on neutrophils, and it is a glycosphosphatidylinositol (GPI)-linked receptor, lacking transmembrane and cytoplasmic domains (10). The signaling mechanism for this receptor is still unknown, since possible signaling molecules directly associated with it remain unidentified. However, several reports show that FcγRIIib can initiate signaling events leading to various cell responses including increase in calcium concentration (11), activation of integrins (12), and activation of NF-κB (13, 14).

FcγRIIib cross-linking induced efficient NET formation similarly to Phorbol 12-myristate 13-acetate (PMA) stimulation (15). This NET formation was dependent on NADPH-oxidase and extracellular signal-regulated kinase (ERK) activation (15). But, the mechanism linking FcγRIIib to ERK is not known. Previously, we reported that FcγRIIib cross-linking led to activation of NF-κB (13); while others have reported that transforming growth factor-β-activated kinase 1 (TAK1) was associated to the IκB kinase complex, both in the nucleus and cytoplasm of human neutrophils favoring NF-κB activation (16). More recently, we also found that FcγRIIib induced a robust activation of ERK and also of the transcription factor Elk-1 (17), but we could not identify the molecule responsible for ERK activation. Similarly, others have reported that, in human neutrophils, TAK1 acted upstream of MEK (ERK kinase) and ERK signaling pathway (18, 19). Thus, in this report, we explored the possibility that TAK1 is functionally coupled to FcγRIIib leading to NETosis via ERK activation. FcγRIIib was stimulated by specific monoclonal antibodies, and the NET formation was evaluated in the presence or absence of pharmacological inhibitors. The antibiotic LL Z1640-2, a selective inhibitor of TAK1 prevented FcγRIIib-induced, but not PMA-induced NET formation. Both PMA and FcγRIIib cross-linking induced phosphorylation of ERK. But, LL Z1640-2 only inhibited the FcγRIIib-mediated activation of ERK. Also, a MEK-specific inhibitor was able to prevent ERK phosphorylation induced by both PMA and FcγRIIib. These data show for the first time that FcγRIIib cross-linking activates TAK1, and that, this kinase is required for triggering the MEK/ERK signaling pathway to NETosis.

MATERIALS AND METHODS

Neutrophils

Neutrophils were isolated from the peripheral blood collected from adult healthy volunteers following a protocol that was approved by the Bioethics Committee at Instituto de Investigaciones Biomédicas – UNAM. All volunteers provided a written informed consent for their blood donation. The procedure for neutrophil isolation was exactly as previously described (14).

Reagents

Bovine serum albumin (BSA) was from F. Hoffmann-La Roche Ltd. (Mannheim, Germany). Piceatannol, a spleen tyrosine kinase (Syk) inhibitor was from Acros Organics (NJ, USA). PD98059 and U0126, MEK (ERK kinase) inhibitors were obtained from New England Biolabs (Beverly, MA, USA) and from Promega (Madison, WI, USA), respectively. The antibiotic LL Z1640-2 [also known as (5Z)-7-Oxozeaenol; catalog no. 66018-38-0] (catalog no. sc-202055) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). GÖ6983, a protein kinase C (PKC) inhibitor, SB 203580, a p38 MAP kinase inhibitor (catalog number 559389), and 3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide (iSyk), another Syk inhibitor (catalog no. 574711) were from Calbiochem/EMD Millipore (Billerica, MA, USA). Recombinant Human TGF-β1 (catalog No. 100-21) was from Peprotech (Rocky Hill, NJ, USA). The cOmplete™ protease inhibitor cocktail (catalog No. 11697498001) and PhosSTOP™ phosphatase inhibitor cocktail (catalog No. 04906845001) were from Roche Diagnostics (Basel, Switzerland). PMA and all other chemicals were from Sigma Aldrich (St. Louis, MO, USA). The following antibodies were used: anti-human FcγRI (CD64) mAb 32.2 (ATCC® HB-946™) and anti-human FcγRIIa (CD32a) mAb IV3 (20) (ATCC® HB-217™) were from American Type Culture Collection (Manassas, VA, USA). The anti-human FcγRIIB (CD16b) mAb 3G8 (21) was donated by Dr. Eric J. Brown (University of California in San Francisco, San Francisco, CA, USA). The anti-β1 integrin mAb TS2/16 was donated by Martin Hemler (Dana Farber Cancer Research Institute, Boston, MA, USA). Monoclonal antibodies were purified as previously described (15).

Rabbit polyclonal anti-ERK 1 (catalog no. sc-94), rabbit polyclonal anti-phospho-ERK 1/2 (pTyr204) (catalog no. sc-101761), and rabbit polyclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (catalog no. sc-25778) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). F(ab′)2 fragment goat anti-mouse IgG (catalog No. 115-006-072) was
from Jackson Immuno Research Laboratories Inc. (West Grove, PA, USA). HRP-conjugated F(ab')2 goat anti-mouse IgG (catalog No. 0855572) and HRP-conjugated F(ab')2 goat anti-rabbit IgG (catalog No. 0855686) were from MP Biomedicals (Santa Ana, CA, USA). Rabbit polyclonal anti-phospho-TAK1 (T187) (catalog No. ab192443) was from Abcam plc. (Cambridge, UK).

**NET Formation Kinetics**

Neutrophil extracellular trap formation was quantified by detecting DNA release spectrophotometrically with the DNA-binding dye SYTOX® Green (22–24). For PMA stimulation, neutrophils were resuspended at $1 \times 10^6$ cell/ml in RPMI-1640 medium (Gibco®; Grand Island, NY, USA) containing 500 nM SYTOX® Green (catalog No. ab192443) was from Abcam plc. (Cambridge, UK).

**Neutrophil Extracellular Trap Formation Kinetics**

Neutrophil extracellular trap formation was quantified by detecting DNA release spectrophotometrically with the DNA-binding dye SYTOX® Green (22–24). For PMA stimulation, neutrophils were resuspended at $1 \times 10^6$ cell/ml in RPMI-1640 medium (Gibco®; Grand Island, NY, USA) containing 500 nM SYTOX® Green (catalog No. ab192443) was from Abcam plc. (Cambridge, UK).

**NET Formation Kinetics**

Neutrophil extracellular trap formation was quantified by detecting DNA release spectrophotometrically with the DNA-binding dye SYTOX® Green (22–24). For PMA stimulation, neutrophils were resuspended at $1 \times 10^6$ cell/ml in RPMI-1640 medium (Gibco®; Grand Island, NY, USA) containing 500 nM SYTOX® Green (catalog No. ab192443) was from Abcam plc. (Cambridge, UK).

**Protein Extraction and Western Blotting**

Total protein extracts were obtained by lysing the cells in cold RIPA lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Heps, 0.5% sodium deoxycholate, 1% Non-ident P-40, 50 mM NaF, and 1 mM sodium orthovanadate, pH 7.5) supplemented with 1X protease inhibitor cocktail and 1X phosphatase inhibitor cocktail, which were added just before lysing the cells. Cell lysates were incubated on ice for 20 min, then cleared by centrifugation, and proteins resolved on SDS 10% PAGE. Proteins were then electrotransferred onto polyvinylidene fluoride (PVDF) membranes (Immobilon-P; Millipore, Bedford, MA, USA). Membranes were incubated in blocking buffer (1% BSA, 5% non-fat dry milk) (Carnation; Nestle, Glendale, CA, USA) and 0.1% Tween 20 in Tris-buffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl, pH = 7.5) overnight at 4°C. Membranes were subsequently probed with the corresponding antibody in blocking buffer for 1 h at room temperature. Anti-phospho-ERK 1 (1/1000 dilution) or anti-phospho TAK1 (1/2000 dilution). Membranes were washed with TBS-Tween six times and incubated with a 1/3000 dilution of HRP-conjugated F(ab')2 goat anti-rabbit IgG o for 1 h at room temperature. After washing six more times, the membrane was developed with Immobilon Western chemiluminescent HRP substrate (catalog No. WBKLS0100) from EMD Millipore (Billerica, MA, USA) according to the manufacturer’s instructions. Afterward, membranes were stripped with 0.2 M NaOH and reprobed with anti-ERK 1 (1/2000 dilution) or anti-GAPDH (1/1000 dilution) to assess protein loading in PAGE gels.

**Statistical Analysis**

Quantitative data were expressed as mean ± SEM. Single variable data were compared by paired-sample Student’s t-tests using the computer program KaleidaGraph® version 3.6.2 for Mac (Synergy
Software; Reading, PA, USA). Differences were considered statistically different at a value $p < 0.05$.

RESULTS

**FcγRIIIb-Mediated NETosis Presents a Different Kinetics from PMA-Induced NETosis**

Most studies on NETs have used PMA, a potent activator of PKC, to induce the formation of NETs (2). Direct cross-linking of FcγRIIIb also leads to a robust activation of NET formation (15). However, the kinetics of these responses is different. When human neutrophils were stimulated by PMA, NETosis (5) is observed as a late event with NETs (extracellular DNA fibers) detected after 2.5 h of stimulation (Figure 1). Complete NET formation was seen, as previously described, by 4 h after stimulation (Figure 1). In contrast, stimulation of FcγRIIIb with mAb 3G8, induced NETosis with a much faster kinetics. By 30 min after receptor cross-linking, NETs could already be detected (Figure 1). By 2 h, about half of the total amount of NETs had already been formed, and by 4 h, NETs reached a level similar to that induced by PMA (Figure 1). In order to confirm that the mAb 3G8 (IgG1) was specifically targeting (cross-linking) FcγRIIIb, neutrophils were also stimulated by the isotypic control antibody TS2/16 (IgG1) that binds to β1 integrins, and by the mAb IV.3 (IgG2b) that binds FcyRIIa. Neither mAb IV.3 nor mAb TS2/16 induced NET formation (Figure 1), strengthening the point that FcγRIIIb is the receptor responsible for induction of NETosis. These data indicated that cross-linking FcγRIIIb is an efficient stimulus for NET formation with a faster response than the one induced by PMA. This difference in response kinetics led us to explore the signaling pathway from FcγRIIIb to NETosis.

**TAK1 Is Involved in FcγRIIIb-Mediated NETosis**

Others and we have seen that the MEK/ERK signaling pathway is required for both PMA- (25) and FcγRIIIb-induced NETosis (15, 23). Because the transforming growth factor-β-activated kinase 1 (TAK1) is a known activator of MAP kinase signaling pathways in various immune cells (26), and in human neutrophils, TAK1 was also reported to act upstream of ERK (18), we explored the possibility that TAK1 is involved in FcγRIIIb-mediated NETosis. The antibiotic LL Z1640-2, a selective inhibitor of TAK1 prevented FcγRIIIb-induced NET formation (Figure 2A), but not PMA-induced NET formation (Figure 2A). The inhibitory effect was maximum at 4 h after stimulation when the amount of NETs from FcγRIIIb-stimulated neutrophils was

![Figure 2](image-url)
reduced by half (Figure 2B). This result indicated for the first time that indeed TAK1 is involved in NET formation after cross-linking FcγRIIIb.

Transforming growth factor-β-activated kinase 1 was initially identified as a regulator of MAPK in response to TGF-β (27), thus, we explored whether TGF-β could have an effect on NETosis. Treatment of neutrophils with TGF-β did not change the kinetics nor the amount of NET formation induced either by FcγRIIIb cross-linking or PMA stimulation (Figure 3). This lack of effect on NETosis was not due to failure of TGF-β to activate TAK1. Neutrophils treated with TGF-β presented a robust phosphorylation of TAK1 (Figure 4A) indicating that the axis TGF-β/TAK1 was functional in these cells. Moreover, cross-linking of FcγRIIIb also led to phosphorylation of TAK1 (Figure 4A). This phosphorylation in Thr-187 is indicative of activation of TAK1 (28). The FcγRIIIb-mediated phosphorylation of TAK1 was detectable at 5 min, reached a maximum at 15 min, and was almost gone by 30 min after receptor cross-linking (Figure 4B). Thus, this time was used in all other experiments to detect TAK1 phosphorylation. Opposite to this result, treatment with PMA did not induce any phosphorylation of TAK1 (Figure 4B).

Human neutrophil expresses constitutively two low-affinity Fcy receptors, FcγRIIa and FcγRIIIb, and after interferon-γ, they can upregulate FcγRI. Previously, it has been reported that FcγRIIIb is the receptor responsible for NET formation (15, 23). Therefore, we explored the possibility that each of these Fc receptors could activate TAK1 after cross-linking each receptor with the corresponding specific monoclonal antibody. Treating the cells with monoclonal antibody 32.2 (anti-FcγRI) did not induce TAK1 phosphorylation (Figure 4C). This was an expected result since FcγRI is not expressed in resting neutrophils. Similarly, cross-linking with monoclonal antibody IV.3 (anti-FcγRIIa) also did not cause any TAK1 phosphorylation (Figure 4C). In contrast, cross-linking of FcγRIIIb with the monoclonal antibody 3G8 efficiently induced TAK1 phosphorylation (Figure 4). Together, these data suggested that, indeed, FcγRIIIb signaling in human neutrophils requires TAK1 activation for induction of NET formation.

**Syk Is Required for FcγRIIIb-Mediated TAK1 Activation**

After establishing a role for TAK1 in FcγRIIIb-mediated NET formation, we explored a possible connection from FcγRIIIb to TAK1. Neutrophils were stimulated by FcγRIIIb cross-linking in the presence or absence of two Syk inhibitors. FcγRIIIb-induced TAK1 phosphorylation and also ERK 1 phosphorylation were
Fig. 5 | Syk is required for FcγRIIIb-mediated TAK1 activation. Human neutrophils were left untreated (---), or were stimulated by cross-linking FcγRIIIb for 15 min in the absence or presence of 50 μM Piceatannol (Pic) or 40 nM iSyk, both selective inhibitors of Syk. Cell lysates were prepared after stimulation. Proteins were resolved by SDS-PAGE and then Western blotted for phosphorylated-TAK1 (pTAK1) (upper panel), or for total ERK (lower panel). Data are representative of three separate experiments.

Fig. 4 | FcγR-cross-linking induces activation of TAK1. Human neutrophils were left untreated (---), or (A) were stimulated with 5 ng/ml transforming growth factor-β (TGF-β), or by cross-linking FcγRIIIb for 15 min. (B) neutrophils were also stimulated with 20 nM phorbol 12-myristate 13-acetate (PMA), or by cross-linking FcγRIIIb (FcR) for 5, 15, and 30 min. (C) neutrophils were also stimulated by cross-linking FcγRI with mAb 32.2, by cross-linking FcγRIIa with mAb IV.3, or by cross-linking FcγRIIib with mAb 3G8 for 15 min. Cell lysates were prepared after stimulation. Proteins were resolved by SDS-PAGE, and then Western blotted for phosphorylated-TAK1 (pTAK1) (upper panel) or for total ERK (lower panel). Data are representative of three separate experiments.

efficiently blocked by both Syk inhibitors (Figure 5). This result suggested that FcγRIIIb connects to TAK1 activation via Syk.

**TAK1 Is Required for FcγRIIIb-Mediated ERK Activation**

Next, we explored the signaling pathway from TAK1 to ERK. Neutrophils were stimulated by PMA or FcγRIIIb cross-linking in the presence or absence of the TAK1 inhibitor, and ERK 1 activation was detected by Western blotting. First, we confirmed that LL Z1640-2 was inhibiting TAK1 phosphorylation (Figure 6A). Under the same conditions, PMA induced ERK phosphorylation (Figure 6B) as previously reported (15). This ERK phosphorylation was not affected by the TAK1 inhibitor (Figure 6B). In contrast, FcγRIIIb cross-linking also induced ERK phosphorylation, but this ERK phosphorylation was efficiently blocked by the TAK1 inhibitor (Figure 6B). This result strongly indicated that TAK1 activation is required for ERK activation after FcγRIIIb cross-linking, but not after PMA stimulation.

In most situations, MEK activation leads to ERK activation, as the former phosphorylates the latter. In order to confirm that this is also the case in the case of FcγRIIIb- or PMA-induced NETosis, neutrophils were treated with the MEK inhibitor PD98059 prior to stimulation. As shown before, cross-linking of FcγRIIIb clearly activated ERK, and this activation was completely blocked by the MEK inhibitor (Figure 7A). Similarly, this MEK inhibitor also blocked ERK activation induced by PMA (Figure 7B). Neither PD98059 nor UO126, another potent MEK inhibitor, was able to block TAK1 activation induced by FcγRIIIb (Figure 7C). This last result confirms that TAK1 is upstream of MEK/ERK signaling module in the case of FcγRIIIb signaling. These data also suggest that the signaling pathways initiated by both FcγRIIIb and PMA converge at the level of PKC or MEK to activate ERK leading to downstream NETosis.
p38 MAPK Is Not Required for FcγRIIIb-Mediated NET Formation

Because it is well known that TAK1 functions upstream of p38 MAPK pathway rather than ERK (26, 29) in many cell types, we examined whether blockade of p38 MAPK affected FcγRIIIb-induced NET formation. The specific p38 MAPK inhibitor SB203580 blocked phosphorylation of p38 MAPK induced by TGF-β (Figure 8A). As expected, neutrophils treated with PMA in the presence of SB203580 produced NETs as efficiently as the neutrophils with no inhibition of p38 MAPK (Figure 8B). Similarly, inhibition of p38 MAPK did not affect NET formation induced by cross-linking FcγRIIIb (Figure 8B). These data strongly suggest that FcγRIIIb activates TAK1 to connect with the MEK/ERK pathway in order to activate NET formation.

DISCUSSION

The MAP3K, TAK1, is activated by different stimuli including cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, and IL-18, or TLR ligands such as LPS in various cell types (26, 30–34) and participates in activating several signaling pathways. In this study, we report for the first time that, in human neutrophils treated with cross-linking FcγRIIIb, TAK1 is required for FcγRIIIb-mediated ERK activation. Human neutrophils were left untreated (---), or were stimulated by cross-linking FcγRIIIb for 15 min, or by 20 nM phorbol 12-myristate 13-acetate (PMA). Some neutrophils were previously treated with 10 nM LL Z1640-2 (LLZ), a selective inhibitor of TAK1. Cell lysates were prepared after stimulation. Proteins were resolved by SDS-PAGE, and then, Western blotted for (A) phosphorylated-TAK1 (pTAK1) (upper panel) and for total GAPDH (lower panel); or for (B) phosphorylated ERK (pERK) and total GAPDH (lower panel). Data are representative of three separate experiments.

Alemán et al. TAK1 in FcγR-Induced NETosis

Frontiers in Immunology | www.frontiersin.org 7 July 2016 | Volume 7 | Article 277
neutrophils, TAK1 can also be activated in response to stimulation of antibody receptor FcγRIIIb. We also show that TAK1 is required for induction of NETosis by this receptor via the MEK/ERK signaling cascade.

Neutrophil activation is required for the initiation of the several defense mechanisms, including phagocytosis, respiratory burst, release of various microbicidal molecules by degranulation (35), and the formation of NETs (3). Many pathogens, including virus, bacteria, fungi, and parasites are known to induce NET formation (6). These microorganisms must be recognized by pattern recognition receptors (PRRs) such as TLRs. In fact, TLR-4 has been identified as an important receptor for NET formation (36–38). In addition, receptors for the Fc portion of antibody molecules have recently been identified as potent inducers of NET formation. In particular, the receptor for IgA FcαRI (CD89) and the receptor for IgG FcγRIIb (CD16b) (15, 23) are the only Fc receptors known to induce NETosis.

FcγRIIIb is present exclusively on human neutrophils, and it is a GPI-linked receptor, lacking transmembrane and cytoplasmic domains (10). Despite the fact that the initial signaling mechanism for this receptor remains to be described, it is clear that it can activate several signaling pathways leading to various cell responses including increase in calcium concentration (11), activation of integrins (12), activation of the transcription factors NF-κB (13) and Elk-1 (17), and induction of NET formation (15, 23). In our previous publication, we described that FcγRIIIb can activate ERK, and this activation is important for NET formation (15). However, we could not identify how the MEK/ERK signaling cascade was engaged. Here, we now report for the first time, as far as we know, that the transforming growth factor-β-activated kinase 1 (TAK1) is activated upon FcγRIIIb engagement, and that this kinase is required both for NET formation and MEK/ERK activation. Our findings are similar to those reported for chemoattractant and growth factor stimulation of neutrophils where TAK1 is also activated and acts upstream of the MEK/ERK pathway (19). Still, the manner in which FcγRIIIb activates TAK1 remains elusive. Possible activators include Syk or TRAF6. We addressed the involvement of Syk by blocking its activity with two different specific inhibitors. Both Piceatannol and iSyk prevented activation (phosphorylation) of both TAK1 and ERK. These data clearly indicate that Syk functions upstream of TAK1 after FcγRIIIb engagement. However, how this receptor lacking a cytoplasmic tail can connect with Syk remains an unsolved problem for future studies.

Although, both stimuli PMA and FcγRIIIb cross-linking initiate signaling that seems to converge at the level of MEK (Figure 9), an important difference in NETosis induced by PMA or by FcγRIIIb was found in this study. PMA release of DNA fibers was detected at later times just as described before (2, 40), more than 2½ h after stimulation, and reached a maximum around 4 h (Figure 1). In contrast, FcγRIIIb-induced NETosis liberated DNA fibers rapidly in less than 1 h (Figure 1). Mechanistically, we do not know the reason for this difference, but it is possible that another pathway in addition to the ERK pathway is involved. Previously, Syk was also found to participate in NET formation induced by insoluble immune complexes (23) and by PMA (23). We also found that inhibition of Syk by Piceatannol blocked the release of NETs induced either by PMA or by FcγRIIIb (15). In addition, we have observed inhibition of FcγRIIIb-mediated TAK1 phosphorylation by Piceatannol and by iSyk (Figure 5). This suggests as mentioned above that Syk is required for TAK1 activation to deliver a signal for NET formation after FcγRIIIb phosphorylation by Piceatannol and by iSyk (Figure 5). This suggests as mentioned above that Syk is required for TAK1 activation to deliver a signal for NET formation after FcγRIIIb

**FIGURE 8** | p38 MAPK is not required for FcγRIIIb-mediated NET formation. (A) Human neutrophils were left untreated (---) or were stimulated with 5 ng/ml transforming growth factor-β (TGF-β). Some neutrophils were previously treated with 100 nM SB 203580, a selective inhibitor of p38 MAPK. Cell lysates were prepared after stimulation. Proteins were resolved by SDS-PAGE, and then Western blotted for phosphorylated-p38 (p-p38) (upper panel) and for total ERK (lower panel). Data are representative of three separate experiments. (B) Human neutrophils were left untreated (---), or were stimulated with 20 nm phorbol 12-myristate 13-acetate (PMA), or by cross-linking FcγRIIIb with mAb 3G8, and then incubated for 4 h. Some neutrophils were previously treated with 100 nM SB 203580 (SB) (open symbols). The relative amount of NETs was estimated from SYTOX® Green fluorescence in relative fluorescent units (RFU) every 5 min. Data are mean ± SEM of three experiments done in triplicates.
engagement. Yet, activation of Syk by PMA has also been previously described in neutrophils. PMA induced PKC-dependent phosphorylation of Syk (41). However, we do not think that this pathway is involved in the case because inhibition of PKC did not prevent FcγRIIIb-induced TAK1 phosphorylation (our unpublished data). Thus, TAK1 acts downstream of FcγRIIIb and upstream (or independently) of PKC (Figure 9). In contrast, inhibition of PKC leads to reduced FcγRIIIb-induced NET formation (15). Hence, it would seem that TAK1 connects to PKC for activation of the MEK/ERK signaling cascade. In support of this idea, another receptor has been recently reported to activate Syk and TAK1 together with PKC. The innate decoy receptor CEACAM3, also exclusively expressed by human neutrophils, triggers a Syk-, PKCδ-, and TAK1-dependent signaling cascade that results in activation of NF-kB (42). In another even more recent report, TAK1 was clearly shown to activate the MEK/ERK pathway (19). Unfortunately, in this study, the involvement of PKC was not investigated. Whether TAK1 connects to MEK directly of via PKC remains unsolved (Figure 9). Also, the difference in kinetics for NET formation might be due, at least in part, to the selective activation of TAK1 by FcγRIIIb (Figure 9). This idea is attractive, since, when neutrophils were treated with TGF-β, a stronger phosphorylation of TAK1 was detected (Figure 4A). Yet, no difference in NET formation was observed in cells pretreated with TGF-β. The mechanism responsible for the faster kinetics in FcγRIIIb-mediated NET formation remains to be elucidated.

In several cell types, TAK1 functions upstream of p38 MAPK pathway rather than ERK (26, 29). In contrast, in human neutrophils, it has been reported that chemotactic and growth factors induce TAK1 activation leading to the MEK/ERK pathway independently of p38 MAPK (19). In the case of FcγRIIIb-induced NET formation, we also found that inhibition of p38 MAPK with the inhibitor SB203580 did not affect NETosis (Figure 8B). Thus, our data also support the hypothesis that, in human neutrophils, TAK1 connects to MEK/ERK and not to p38 MAPK or JNK.

In conclusion, to our knowledge, this is the first demonstration that TAK1 can be activated by FcγRIIIb in human neutrophils, and that this kinase is required for triggering the MEK/ERK signaling pathway to NETosis.

**AUTHOR CONTRIBUTIONS**

OA performed most of the experiments for NET formation and analyzed the data. NM prepared the cells and performed Western blots. RC-V generated some of the Western blot data. EU-Q helped with the first draft, performed the statistical analysis, organized the references, and prepared all figures. CR designed the research, mentored all other authors, and wrote the final version of the paper.

**ACKNOWLEDGMENT**

RC-V was the recipient of a post doc fellowship from Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México, Mexico.

**FUNDING**

Research in the authors’ laboratory was supported by grant 254434 from Consejo Nacional de Ciencia y Tecnología, Mexico (to CR), and by grants PAPIIT IA202013–2 (to EU-Q), and IN207514 (to CR) from Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México, Mexico.

**REFERENCES**

1. Mócsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. *J Exp Med* (2013) 210(7):1283–99. doi:10.1084/jem.20122220
2. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uehlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Science* (2004) 303:1532–5. doi:10.1126/science.1092385
3. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytnuik LD, et al. Infection-induced NETosis is a dynamic process involving neutrophil multisking in vivo. *Nat Med* (2012) 18(9):1386–93. doi:10.1038/nm.2847
4. Neeli I, Radic M. Knotting the NETs: analyzing histone modifications in neutrophil extracellular traps. *Arthritis Res Ther* (2012) 14(2):115. doi:10.1186/ar3773
5. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol* (2007) 176:231–41. doi:10.1083/jcb.200606027
6. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. *Trends Immunol* (2009) 30(11):513–21. doi:10.1016/j.it.2009.07.011
7. Unkeless JC, Shen Z, Lin CW, DeBeus E. Function of human FcγRIIA and FcγRIIB. *Semin Immunol* (1995) 7(1):37–44. doi:10.1016/1044-5323(95)90066-3
8. Rosales C, Uribe-Querol E. Antibody–Fc receptor interactions in antimicrobial functions. *Curr Immunol Rev* (2013) 9:44–55. doi:10.2174/1573395511309010006
9. Rosales C, Uribe-Querol E. Fc receptors: cell activators of antibody functions. *Adv Biosci Biotech* (2013) 4:21–33. doi:10.4236/abb.2013.44A004
Alemán OR, Mora N, Cortes-Vieyra R, Uribe-Querol E, Rosales C. Differential use of human neutrophil Fc receptors for inducing neutrophil extracellular trap formation. J Leukoc Biol (2015) 98(4):565–73. doi:10.1187/jlb.2MA1214-599R

Sylvain-Prévost S, Ear T, Simard A, Vardhan H, McDonald PP. MEK-inked ERK activation in human neutrophils and its impact on functional responses. J Leukoc Biol (2015) 98(4):565–73. doi:10.1187/jlb.2MA1214-599R

Sijmons RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol (1995) 155(4):1641–7.

Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci U S A (1982) 79:3275–9. doi:10.1073/pnas.79.12.3275

Vong L, Sherman PM, Glogauer M. Quantification and visualization of neutrophil extracellular traps (NETs) from murine bone marrow-derived neutrophils. Methods Mol Biol (2013) 1031:41–50. doi:10.1007/978-1-62703-481-4_5

Behnen M, Leschczyk C, Moller S, Batel T, Klinger M, Solbach W, et al. Immobilized immune complexes induce neutrophil extracellular trap release by human peripheral blood neutrophils detected by a novel flow cytometry-based method. PLoS One (2015) 10(4):e0124082. doi:10.1371/journal.pone.0124082

Awasthi D, Nagarokti S, Kumar A, Dubey M, Singh AK, Pathak P, et al. Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. Free Radic Biol Med (2016) 93:190–203. doi:10.1016/j.freeradbiomed.2016.01.004

Aleyd E, van Hout MW, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, et al. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via FcR receptor I. J Immunol (2014) 192(5):2374–83. doi:10.4049/jimmunol.1300261

Birkenmann V, Laube B, Abu Abed U, Goosmann C, Zychlinsky A. Neutrophil extracellular traps: how to generate and visualize them. J Vis Exp (2010) 36:1724. doi:10.3791/1724

Popa-Nita O, Proulx S, Paré G, Rollet-Labelle E, Naccache PH. Crystal-induced extracellular trap formation by human neutrophils. J Biol Chem (2005) 280(8):7359–68. doi:10.1074/jbc.M407537200

Singhrunusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem (2005) 280(8):7359–68. doi:10.1074/jbc.M407537200

Copyright © 2016 Alemán, Mora, Cortes-Vieyra, Uribe-Querol and Rosales. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.